Tumor cell vaccines

Advances in Experimental Medicine and Biology

Volumn 601, Issue , 2007, Pages 345-355

  Thompson, Patricia L ^a   Dessureault, Sophie ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; TUMOR ANTIGEN;

ALLOTRANSPLANTATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM; REVIEW; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34848880827     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-72005-0_37     Document Type: Conference Paper

References (42)

1. Antonia, S.J., Seigne, J., Diaz, J., Muro-Cacho, C., Extermann, M., Farmelo, M.J., Friberg, M., Alsarraj, M., Mahany, J.J., Pow-Sang, J., Cantor, A. and Janssen, W. (2002) Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin- 2 in patients with metastatic renal cell carcinoma. J. Urol. 167, 1995-2000.
2. Arroyo, P.J., Bash, J.A., Wallack, M.K., Arroyo, P.J., Bash, J.A. and Wallack, M.K. (1990) Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol. Immunother. 31, 305-311.
3. Banchereau, J. and Steinman, R.M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
4. Bash, J.A. (1993) Active specific immunotherapy of murine colon adenocarcinoma with recombinant vaccinia/interleukin-2-infected tumor cell vaccines. Ann. NY Acad. Sci. 690, 331-333.
5. Berd, D. (2004) M-Vax: An autologous, hapten-modified vaccine for human cancer. Expert Rev. Vaccines 3, 521-527.
6. Bluestone, J.A. (1998) Cell fate in the immune system: Decisions, decisions, decisions. Immunol. Rev. 165, 5-12.
7. Bronte, V., Carroll, M.W., Goletz, T.J. Wang, M., Overwijk, W.W., Marincola, F., Rosenberg, S.A., Moss, B. and Restifo, N.P. (1997) Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc. Nat. Acad. Sci. USA 94, 3183-3188.
8. Bystryn, J.C. (1993) Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens. Ann. of the NY Acad. Sci. 690, 190-203.
9. Bystryn, J.C., Henn, M., Li, J. and Shroba, S. (1992a) Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine. Cancer Res. 52, 5948-5953.
10. Bystryn, J.C., Oratz, R., Roses, D., Harris, M., Henn, M. and Lew, R. (1992b) Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69, 1157-1164.
11. Colombo, M.P. and Forni, G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol. Today 15, 48-51.
12. Colombo, M.P. and Rodolfo, M. (1995) Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: Do animal studies really support clinical trials? Cancer Immunol. Immunother. 41, 265-270.
13. Durrant, L.G. and Spendlove, I. (2003) Cancer vaccines entering phase III clinical trials. Expert Opin. Emerg. Drugs 8, 489-500.
14. Halpern, B.N., Biozzi, G., Stiffel, C. and Mouton, D. (1966) Inhibition of tumour growth by administration of killed Corynebacterium parvum. Nature 212, 853-854.
15. Hanna, M.G., Jr., Hoover ,H.C., Jr., Vermorken, J.B., Harris, J.E. and Pinedo, H.M. (2001) Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: First randomized phase III trials show promise. Vaccine 19, 2576-2582.
16. Hom, S.S., Schwartzentruber, D.J., Rosenberg, S.A. and Topalian, S.L. (1993) Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J. Immunother. 13, 18-30.
17. Hsueh, E.C., Famatiga, E., Gupta, R.K., Qi, K. and Morton, D.L. (1998) Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): Correlation with survival. Ann. Surg. Oncol. 5, 595-602.
18. Itoh, K., Platsoucas, C.D. and Balch, C.M. (1988) Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J. Exp. Med. 168, 1419-1441.
19. Jaffee, E.M., Hruban, R.H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P.R., Goemann, M., Coleman, J., Grochow, L., Donehower, R.C., Lillemoe, K.D., O'Reilly, S., Abrams, R.A., Pardoll, D.M., Cameron, J.L. and Yeo, C.J. (2001) Novel allogeneic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J. Clin. Oncol. 19, 145-156.
20. Johnston, D., Rouby, S. and Bystryn, J.C. (1994) Identification of melanoma cell surface antigens immunogenic in mice. Cancer Biother. 9, 29-38.
21. Klein, G., Sjogren, H.O., Klein, E. and Hellstrom, K.E. (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572.
22. Kusumoto, M., Umeda, S., Ikubo, A., Aoki, Y., Tawfik, O., Oben, R., Williamson, S., Jewell, W. and Suzuki, T. (2001) Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50, 373-381.
23. Leach, D.R., Krummel, M.F. and Allison, J.P. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736.
24. Livingston, P.O., Albino, A.P., Chung, T.J. Real, F.X., Houghton, A.N., Oettgen, H.F. and Old, L.J. (1985) Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer 55, 713-720.
25. Marshall, M. (2003) Development of therapeutic cancer vaccines conference, 27-29 April 2003. Cancer Immunol. Immunother. 52, 648-654.
26. McCune, C.S., O'Donnell, R.W., Marquis, D.M. and Sahasrabudhe, D.M. (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. 32, 62-66.
27. Mitchell, M.S. (1998) Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin. Oncol. 25, 623-635.
28. Mitchell, M.S. (2002a) Cancer vaccines, a critical review-Part I. Curr. Opin. Invest. Drugs 3, 140-149.
29. Mitchell, M.S. (2002b) Cancer vaccines, a critical review-Part II. Curr. Opin. Invest. Drugs 3, 150-158.
30. Morton, D.L., Hsueh, E.C., Essner, R., Foshag, L.J., O'Day, S.J., Bilchik, A., Gupta, R.K., Hoon, D.S., Ravindranath, M., Nizze, J.A., Gammon, G., Wanek, L.A., Wang, H.J. and Elashoff, R.M. (2002) Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Surg, 236, 438-448.
31. Pardoll, D.M. (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13, 399-415.
32. Prehn, R.T. (1975) Relationship of tumor immunogenicity to concentration of the oncogen. J. Nat. Cancer Inst. 55, 189-190.
33. Prehn, R.T. and Main, J.M. (1957) Immunity to methylcholanthrene-induced sarcomas. J. Nat. Cancer Inst. 18, 769-778.
34. Sahasrabudhe, D.M., deKernion, J.B., Pontes, J.E., Ryan, D.M., O'Donnell, R.W., Marquis, D.M., Mudholkar, G.S. and McCune, C.S. (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Response Mod. 5, 581-594.
35. Salgaller, M.L. and Lodge, P.A. (1998) Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol. 68, 122-138.
36. Salgia, R., Lynch, T., Skarin, A., Lucca, J., Lynch, C., Jung, K., Hodi, F.S., Jaklitsch, M., Mentzer, S., Swanson, S., Lukanich, J., Bueno, R., Wain, J., Mathisen, D., Wright, C., Fidias, P., Donahue, D., Clift, S., Hardy, S., Neuberg, D., Mulligan, R., Webb, I., Sugarbaker, D., Mihm, M. and Dranoff, G. (2003) Vaccination with irradiated autologoustumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630.
37. Schultz, N., Oratz, R., Chen, D., Zeleniuch-Jacquotte, A., Abeles, G. and Bystryn, J.C. (1995) Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 13, 503-508.
38. Sondak,V.K. and Sosman, J.A. (2003) Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin. Cancer Biol. 13, 409-415.
39. Van Epps, D. (2004) Characterization of polyvalent allogeneic vaccines. Dev. Biol. 116, 79-90.
40. Vermorken, J.B., Claessen, A.M., van Tinteren, H., Gall, H.E., Ezinga, R., Meijer, S., Scheper, R.J., Meijer, C.J., Bloemena, E., Ransom, J.H., Hanna, M.G., Jr. and Pinedo, H.M. (1999) Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 353, 345-350.
41. White, P.J. and Shackelford, P.G. (1983) Edward Jenner, MD, and the scourge that was. Am. J. Dis. Child. 137, 864-869.
42. Wiemann, B. and Starnes, C.O. (1994) Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol. Ther. 64, 529-564.